BIIB News and Press, Biogen Inc. From 05/23/24

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of all persons and entities who purchased securities of Biogen, Inc. (“Biogen&...

2024-05-22 11:44:10 ET More on IGM Biosciences IGM Biosciences: Unlikely To Move The Needle Again In 2024 IGM Biosciences GAAP EPS of -$0.83 misses by $0.01, revenue of $0.5M misses by $0.28M IGM Biosciences announces refocusing of Sanofi collaboration Seekin...

2024-05-22 11:00:10 ET Matthew Harrison from Morgan Stanley issued a price target of $331.00 for BIIB on 2024-05-22 09:25:00. The adjusted price target was set to $331.00. At the time of the announcement, BIIB was trading at $224.48. The overall price target consensus is...

2024-05-22 08:42:49 ET More on Biogen Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings Biogen: Don't Overthink This One Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade) Biogen also drops collaboration with Ionis on Angelman syndrome candidat...

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases Felzartamab is an investigational anti-CD38 monoclonal antibody that, through its cell depletion approach, has demonstrated c...

2024-05-20 18:17:01 ET More on Larimar Therapeutics Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earnings data for Larimar Therapeutics Financial information for Larimar Therapeutics Read the full article on Seeking Alpha For...

2024-05-17 06:15:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With innovation, millions of retiring baby boomers, demand for better care, patent cliffs, gene-editing, massive interest in weight-loss treatments, and an increase in mergers, biotech stocks...

2024-05-16 13:47:53 ET More on Biogen, Ionis Pharmaceuticals Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings Biogen: Don't Overthink This One Biogen and Ionis drop ALS candidate after trial setback Eisai projects major growth for Alzheimer's therapy L...

2024-05-16 09:00:18 ET More on Biogen, Ionis, etc. Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings Biogen: Don't Overthink This One Eisai projects major growth for Alzheimer's therapy...

Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impa...